RESUMEN
Lansoprazole is an inhibitor of gastric acid secretion and also exhibits antibacterial activity against Helicobacter pylori in vitro. Current therapy for peptic ulcer disease focuses on the eradication of H. pylori infection with maintenance therapy indicated in those patients who are not cured of H. pylori and those with ulcers resistant to healing. Lansoprazole 30 mg combined with amoxicillin 1g, clarithromycin 250 or 500mg, or metronidazole 400 mg twice daily was associated with eradication rates ranging from 71 to 94%, and ulcer healing rates were generally >80% in well designed studies. In addition, it was as effective as omeprazole- or rabeprazole-based regimens which included these antimicrobial agents. Maintenance therapy with lansoprazole 30 mg/day was significantly more effective than either placebo or ranitidine in preventing ulcer relapse. Importantly, preliminary data suggest that lansoprazole-based eradication therapy is effective in children and the elderly. In the short-term treatment of patients with gastro-oesophageal reflux disease (GORD), lansoprazole 15, 30 or 60 mg/day was significantly more effective than placebo, ranitidine 300 mg/day or cisapride 40 mg/day and similar in efficacy to pantoprazole 40 mg/day in terms of healing of oesophagitis. Lansoprazole 30 mg/day, omeprazole 20 mg/day and pantoprazole 40 mg/day all provided similar symptom relief in these patients. In patients with healed oesophagitis. 12-month maintenance therapy with lansoprazole 15 or 30 mg/day prevented recurrence and was similar to or more effective than omeprazole 10 or 20 mg/day. Available data in patients with NSAID-related disorders or acid-related dyspepsia suggest that lansoprazole is effective in these patients in terms of the prevention of NSAID-related gastrointestinal complications, ulcer healing and symptom relief. Meta-analytic data and postmarketing surveillance in >30,000 patients indicate that lansoprazole is well tolerated both as monotherapy and in combination with antimicrobial agents. After lansoprazole monotherapy commonly reported adverse events included dose-dependent diarrhoea, nausea/vomiting, headache and abdominal pain. After short-term treatment in patients with peptic ulcer, GORD, dyspepsia and gastritis the incidence of adverse events associated with lansoprazole was generally < or = 5%. Similar adverse events were seen in long-term trials, although the incidence was generally higher (< or = 10%). When lansoprazole was administered in combination with amoxicillin, clarithromycin or metronidazole adverse events included diarrhoea, headache and taste disturbance. In conclusion, lansoprazole-based triple therapy is an effective treatment option for the eradication of H. pylori infection in patients with peptic ulcer disease. Preliminary data suggest it may have an important role in the management of this infection in children and the elderly. In the short-term management of GORD, lansoprazole monotherapy offers a more effective alternative to histamine H2-receptor antagonists and initial data indicate that it is an effective short-term treatment option in children and adolescents. In adults lansoprazole maintenance therapy is also an established treatment option for the long-term management of this chronic disease. Lansoprazole has a role in the treatment and prevention of NSAID-related ulcers and the treatment of acid-related dyspepsia; however, further studies are needed to confirm its place in these indications. Lansoprazole has emerged as a useful and well tolerated treatment option in the management of acid-related disorders.
Asunto(s)
Antiulcerosos/uso terapéutico , Enfermedades Gastrointestinales/tratamiento farmacológico , Omeprazol/análogos & derivados , Omeprazol/uso terapéutico , 2-Piridinilmetilsulfinilbencimidazoles , Animales , Antiinflamatorios no Esteroideos/efectos adversos , Antiulcerosos/administración & dosificación , Antiulcerosos/efectos adversos , Antiulcerosos/farmacología , Dispepsia/tratamiento farmacológico , Enfermedades Gastrointestinales/etiología , Humanos , Lansoprazol , Omeprazol/administración & dosificación , Omeprazol/efectos adversos , Omeprazol/farmacología , Úlcera Péptica/inducido químicamente , Úlcera Péptica/tratamiento farmacológicoRESUMEN
The fixed low-dose combination of the ACE inhibitor perindopril and the non-thiazide diuretic indapamide has been evaluated in the management of patients with mild to moderate hypertension. Combination therapy aims to improve overall therapeutic efficacy while minimising adverse effects. In well-designed multicentre clinical trials, perindopril/indapamide at doses ranging from 2/0.625 to 8/2.5 mg/day was significantly more effective than placebo in achieving adequate blood pressure (BP) control. A similar reduction in supine BP was observed when combined perindopril/indapamide 2/0.625 mg/day was compared with losartan 50 mg/day or atenolol 50 mg/day. Similar reductions in 24-hour ambulatory BP were also seen with perindopril/indapamide 2/0.625 mg/day and irbesartan 150 mg/day. However, response and normalisation rates were significantly higher with combination therapy than with losartan or irbesartan monotherapy. Combined perindopril/indapamide 2/0.625 mg/day therapy effectively reduced BP in elderly patients aged 65 to 85 years to a significantly greater extent than either atenolol 50 mg/day or placebo. Supine BP was also normalised in approximately two-thirds of patients in a small noncomparative trial in patients with hypertension and renal impairment. Low-dose perindopril/indapamide 2/0.625 mg/day was well tolerated in clinical trials; the most common adverse events were headache and cough. Hypokalaemia, associated with the use of diuretics, occurred with a higher incidence with combined perindopril/indapamide 2/0.625 mg/day therapy than with either atenolol 50 mg/day or placebo. Perindopril/indapamide 2/0.625 mg/day has shown efficacy in well designed comparative trials with atenolol, losartan and irbesartan including elderly patients and patients with renal impairment. Studies comparing this dosage of perindopril/ indapamide with other combination therapies would be beneficial in allowing the place of perindopril/indapamide to be more accurately determined. The fixed-low dose combination of perindopril/indapamide provides a promising and well tolerated treatment option in the management of patients with mild to moderate hypertension.
Asunto(s)
Antihipertensivos/administración & dosificación , Antihipertensivos/farmacología , Hipertensión/diagnóstico , Indapamida/administración & dosificación , Indapamida/farmacología , Perindopril/administración & dosificación , Perindopril/farmacología , Adulto , Factores de Edad , Anciano , Animales , Antihipertensivos/efectos adversos , Antihipertensivos/farmacocinética , Presión Sanguínea/efectos de los fármacos , Modelos Animales de Enfermedad , Humanos , Hipertrofia Ventricular Izquierda/inducido químicamente , Hipopotasemia/inducido químicamente , Indapamida/efectos adversos , Indapamida/farmacocinética , Enfermedades Renales/inducido químicamente , Persona de Mediana Edad , Perindopril/efectos adversos , Perindopril/farmacocinética , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day. Rofecoxib has greater selectivity for COX-2 than celecoxib, meloxicam, diclofenac and indomethacin. In well-controlled clinical trials, rofecoxib 12.5 to 500 mg/day has been evaluated for its efficacy in the treatment of osteoarthritis, acute pain and rheumatoid arthritis [lower dosages (5 to 125 mg/day) were generally used in the chronic pain indications]. In the treatment of patients with osteoarthritis, rofecoxib was more effective in providing symptomatic relief than placebo, paracetamol (acetaminophen) and celecoxib and was similar in efficacy to ibuprofen, diclofenac, naproxen and nabumetone. Overall, both the physician's assessment of disease status and the patient's assessment of response to therapy tended to favour rofecoxib. In patients with postsurgical dental pain, pain after spinal fusion or orthopaedic surgery, or primary dysmenorrhoea, rofecoxib provided more rapid and more sustained pain relief and reduced requirements for supplemental morphine use after surgery than placebo. Rofecoxib was more efficacious than celecoxib in patients with acute dental pain and pain after spinal fusion surgery, although celecoxib may have been used at a subtherapeutic dose. In comparison with traditional nonsteroidal anti-inflammatory drugs (NSAIDs) ibuprofen, diclofenac and naproxen sodium, rofecoxib was similar in efficacy in the treatment of acute pain. Although naproxen sodium provided more rapid pain relief than rofecoxib in patients with primary dysmenorrhoea, the reverse was true after orthopaedic surgery: rofecoxib provided more rapid pain relief and less supplemental morphine was needed. Rofecoxib was as effective as naproxen in providing symptomatic relief for over 8700 patients with rheumatoid arthritis. Compared with traditional NSAID therapy, rofecoxib had a significantly lower incidence of endoscopically confirmed gastroduodenal ulceration and, in approximately 13,000 patients with osteoarthritis and rheumatoid arthritis, a lower incidence of gastrointestinal (GI) adverse events. Rofecoxib was generally well tolerated in all indications with an overall tolerability profile similar to traditional NSAIDs. The most common adverse events in rofecoxib recipients were nausea, dizziness and headache. In conclusion, rofecoxib is at least as effective as traditional NSAID therapy in providing pain relief for both chronic and acute pain conditions. Rofecoxib provides an alternative treatment option to traditional NSAID therapy in the management of symptomatic pain relief in patients with osteoarthritis. Initial data from patients with primary dysmenorrhoea and postoperative pain are promising and further trials may confirm its place in the treatment of these indications. Rofecoxib has also shown promising results in patients with rheumatoid arthritis and is likely to become a valuable addition to current drug therapy for this patient population. Importantly, rofecoxib is associated with a lower incidence of GI adverse events than traditional NSAIDs making it a primary treatment option in patients at risk of developing GI complications or patients with chronic conditions requiring long term treatment.
Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Inhibidores de la Ciclooxigenasa/uso terapéutico , Lactonas/uso terapéutico , Osteoartritis/tratamiento farmacológico , Dolor/tratamiento farmacológico , Enfermedad Aguda , Animales , Ensayos Clínicos como Asunto , Humanos , Lactonas/farmacocinética , Lactonas/farmacología , Dolor Postoperatorio/tratamiento farmacológico , SulfonasRESUMEN
UNLABELLED: Desirudin, a recombinant hirudin used in the prevention and management of thromboembolic disease, is a thrombin inhibitor which binds directly and with high affinity to clot-bound and fluid phase thrombin. As a prophylaxis in patients undergoing hip replacement surgery, desirudin was significantly more effective in reducing the incidence of deep vein thrombosis (DVT) than either unfractionated or low molecular weight heparin. However, results in patients with acute coronary syndromes are less conclusive. A significant reduction with desirudin compared with heparin in the incidence of death or non-fatal (re)infarction at 24 hours in patients with acute myocardial infarction (MI) was reported in the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) IIb trial but not in the TIMI (Thrombolysis and Thrombin Inhibition in Myocardial Infarction) 9B trial. Despite the early reduction shown in GUSTO IIb, desirudin was not associated with an improved long term clinical benefit at 30 days compared with heparin. Similar results were seen in patients with unstable angina/non-Q-wave MI enrolled in the GUSTO IIb trial. In addition, desirudin and heparin showed similar efficacy in preventing restenosis 30 weeks after coronary angioplasty for unstable angina, despite desirudin being associated with a significant reduction in the rate of cardiac events within the first 96 hours. Desirudin is as well tolerated as heparin with a similar incidence of moderate and severe bleeding, intracranial haemorrhage or stroke reported when trialled in the prevention of DVT associated with hip replacement surgery or the treatment of acute coronary syndromes. However, in the GUSTO IIb trial a significantly higher incidence of transfusions was observed in patients with unstable angina/non-Q-wave MI. CONCLUSIONS: Desirudin is clearly more effective than heparin in the prevention of DVT in patients undergoing elective hip replacement, although cost factors may influence its ultimate place in therapy. In the treatment of acute coronary syndromes the role of desirudin is less certain; however, it may be useful for patients in whom heparin therapy is not a viable option.
Asunto(s)
Anticoagulantes/farmacología , Hirudinas/análogos & derivados , Hirudinas/farmacología , Proteínas Recombinantes/farmacología , Tromboembolia/prevención & control , Angina de Pecho/complicaciones , Anticoagulantes/administración & dosificación , Anticoagulantes/farmacocinética , Artroplastia de Reemplazo de Cadera/efectos adversos , Esquema de Medicación , Hirudinas/administración & dosificación , Hirudinas/farmacocinética , Humanos , Infarto del Miocardio/complicaciones , Complicaciones Posoperatorias/prevención & control , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacocinética , Tromboembolia/etiologíaRESUMEN
UNLABELLED: DTaP3-CB (Triacelluvax) is an acellular pertussis (aP) vaccine containing 3 antigens from purified Bordetella pertussis bacteria combined with diphtheria and tetanus toxoids (DT). In addition to purified filamentous haemagglutinin and pertactin, DTaP3-CB contains pertussis toxin which has been genetically rather than chemically detoxified. As shown in randomised, double-blind clinical trials in infants, DTaP3-CB elicits an immune response similar to or greater than that of whole cell (DTwP) vaccines. Results of a large multicentre study comparing DTaP3-CB with 12 acellular and 1 DTwP vaccine indicate that DTaP3-CB, like all acellular vaccines, induces variable immune responses to different pertussis antigens; however, antibody titres to pertussis toxin are normally higher after immunisation with the genetically detoxified vaccine than with other 3- or 4-component vaccines. When given as a fourth or fifth booster dose, DTaP3-CB produced a significant immune response in infants primed with 3 doses of either a DTaP or DTwP vaccine. Virtually all infants immunised with DTaP3-CB had a serological response to diphtheria and tetanus toxoids. Data from 2 very large efficacy studies indicate that DTaP3-CB has high and long lasting protective efficacy against culture-confirmed pertussis which is greater than that of a 2-component vaccine (DTaP2-SB) and the whole cell DTwP-CON vaccine after a 3-, 5- and 12-month immunisation schedule and after a 2-, 4- and 6-month schedule with the DTwP-CON vaccine. However, the DTwP-CON whole cell vaccine has been noted for its low immunogenicity in 1 study and low efficacy and immunogenicity in another study. On the other hand, DTaP3-CB vaccine has similar efficacy to DTaP3-SB (after immunisation at 2, 4 and 6 months), DTaP5-CON and DTwP-EVANS against culture-confirmed pertussis with > or =21 days cough in infants immunised according to a 3-, 5- and 12-month schedule. Infants immunised with DTaP3-CB experienced significantly fewer adverse events such as pain, redness, swelling and irritability than infants given DTwP. DTaP3-CB has a similar tolerability profile to other acellular vaccines and is associated with similar rates of local tenderness, irritability, fever (> or =40 degrees C) and persistent crying. Comparative trials have shown that infants immunised with DTaP3-CB had a lower incidence of pain at the site of injection and fever (> or =38 degrees C) compared with other acellular vaccines, although this may have little clinical significance. Concomitant administration of DTaP3-CB with hepatitis B, oral polio or Haemophilus influenzae type B vaccines did not affect the immunogenicity of these other paediatric vaccines. CONCLUSION: Data from clinical trials with DTaP3-CB vaccine indicate that this vaccine induces high and long lasting efficacy. It is at least as efficacious as most whole cell vaccines and generally similar in efficacy to the most efficacious acellular pertussis vaccines containing 3 or more pertussis antigens. DTaP3-CB is better tolerated than whole cell vaccines and has a similar tolerability profile to other acellular vaccines; the possible lower risk of severe adverse events remains to be confirmed. The low reactogenicity of DTaP3-CB is likely to make it well tolerated and therefore well accepted for the immunisation of infants, thereby enabling wider implementation of vaccination programmes.
Asunto(s)
Bordetella pertussis , Vacuna contra Difteria, Tétanos y Tos Ferina/inmunología , Tos Ferina/prevención & control , Niño , Vacuna contra Difteria, Tétanos y Tos Ferina/administración & dosificación , Vacuna contra Difteria, Tétanos y Tos Ferina/efectos adversos , Humanos , Inmunización Secundaria , Tos Ferina/microbiologíaRESUMEN
UNLABELLED: Ropinirole, a non-ergoline dopamine agonist, has selective affinity for dopamine D2-like receptors and little or no affinity for non-dopaminergic brain receptors. Ropinirole is indicated as adjunct therapy to levodopa in patients with advanced Parkinson's disease. It is also indicated, and recent clinical trials have focused on its use, as monotherapy in patients with early Parkinson's disease. In the symptomatic treatment of early Parkinson's disease ropinirole monotherapy was significantly more effective than placebo in 2 multicentre, randomised, double-blind trials of 3 to 12 months duration as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and Clinical Global Impression/Clinical Global Evaluation Scales. In a similarly designed 3-year comparative study with bromocriptine, ropinirole recipients showed a significant improvement in UPDRS- activities of daily living (ADL) scores; however, motor scores were similar between the 2 groups. Ropinirole and levodopa treatments were similar in efficacy as measured by UPDRS ADL scores, although ropinirole recipients showed significantly less improvement on UPDRS motor scores at the 5-year study end-point in a multicentre, randomised double-blind trial. As an adjunct therapy to levodopa in patients with more advanced Parkinson's disease, ropinirole was reported to be as effective as bromocriptine and significantly more effective than placebo. In general in the comparisons with placebo ropinirole allowed a > or =20% reduction in the concomitant dose of levodopa without compromising efficacy in a significant proportion of patients and, in some trials decreased the amount of awake time spent in the 'off' state ('off' state is defined as a gradual return to parkinsonism despite adequate medication). Ropinirole was well tolerated either as monotherapy or as an adjunct to levodopa treatment. Nausea, dizziness and somnolence were the most commonly reported adverse events and were reported at a higher incidence by patients receiving ropinirole than by those receiving placebo. In patients with early Parkinson's disease, ropinirole generally showed a similar overall tolerability profile to bromocriptine although, over a 3-year period nausea was more commonly reported with ropinirole recipients. In a 5-year study, the incidence of dyskinesia was significantly lower with ropinirole than with levodopa regardless of levodopa supplementation. Prior to the addition of supplementary levodopa 5% of ropinirole recipients had experienced dyskinesia compared with 36% of those receiving levodopa. CONCLUSIONS: In patients with early Parkinson's disease, ropinirole monotherapy was more efficacious than bromocriptine with regard to improvement in activities of daily living, and need for supplemental levodopa. Ropinirole recipients had a higher requirement for levodopa supplementation than levodopa recipients in a 5-year study, but the incidence of dyskinesia was significantly lower with ropinirole than with levodopa (markedly so in the one third of ropinirole recipients who were able to remain on monotherapy with no levodopa supplementation). Thus available data suggest that ropinirole may provide a means of treating early Parkinson's disease while minimising the risk of dyskinesia and delaying the need for supplemental levodopa in some patients. In addition, ropinirole is also efficacious in the management of more advanced Parkinson's disease in patients who are experiencing motor complications after long term levodopa use.
Asunto(s)
Antiparkinsonianos , Indoles , Enfermedad de Parkinson/tratamiento farmacológico , Anciano , Antiparkinsonianos/farmacocinética , Antiparkinsonianos/farmacología , Antiparkinsonianos/uso terapéutico , Ensayos Clínicos como Asunto , Humanos , Indoles/farmacocinética , Indoles/farmacología , Indoles/uso terapéutico , Enfermedad de Parkinson/fisiopatologíaRESUMEN
Racecadotril is an oral enkephalinase inhibitor used in the treatment of acute diarrhoea. It prevents the degradation of endogenous opioids (enkephalins), thereby reducing hypersecretion of water and electrolytes into the intestinal lumen. In a randomised double-blind study in 6 adult volunteers with castor oil-induced diarrhoea, racecadotril significantly reduced stool weight and stool number in comparison with placebo. Similar results have been obtained in treating castor oil-induced diarrhoea in rats. Racecadotril was significantly more effective than placebo in randomised double-blind studies in adults or children with diarrhoea (of infectious origin or in adults with HIV infection). In well controlled trials, racecadotril had efficacy similar to that of loperamide and was generally as effective as loperamide-oxide. Racecadotril had a similar tolerability profile to placebo, and was better tolerated than loperamide, in adults and children with diarrhoea. It caused significantly less constipation after resolution of diarrhoea than loperamide.
Asunto(s)
Antidiarreicos/farmacología , Tiorfan/análogos & derivados , Animales , Antidiarreicos/efectos adversos , Antidiarreicos/farmacocinética , Antidiarreicos/uso terapéutico , Humanos , Tiorfan/efectos adversos , Tiorfan/farmacocinética , Tiorfan/farmacología , Tiorfan/uso terapéuticoRESUMEN
The aim of the present study was to investigate the effects of aging on postural function in human subjects. Subjects aged 18-39 years (n = 24), 40-59 years (n = 24) and 60 years or older (n = 27) were tested for postural stability using an electronic balance platform. There was a significant increase in postural instability with increasing age (P < 0.0001), and as the conditions of testing became more difficult (P < 0.0001) (e.g., with eyes closed). Elderly males were found to have significantly poorer postural control than elderly females in the visual-vestibular conflict conditions (P < 0.05). These results further demonstrate a decline in postural function with increasing age, which may be related to deterioration in the peripheral or central vestibular systems and may be partly responsible for the high incidence of falls in the elderly.
Asunto(s)
Accidentes por Caídas/prevención & control , Envejecimiento/fisiología , Equilibrio Postural/fisiología , Postura/fisiología , Adulto , Factores de Edad , Análisis de Varianza , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores SexualesRESUMEN
Previous studies have shown that experience with optokinetic stimulation can alter a subject's sensitivity to illusions such as circularvection (CV). The aim of the present experiment was to compare optokinetic nystagmus (OKN), optokinetic afternystagmus (OKAN), and sensitivity to CV between 2 groups of sportspeople: 1) squash players (n = 16), who regularly experience vigorous optokinetic stimulation while engaging in their sporting activity, and 2) weightlifters (n = 16), whose sport does not involve the same degree of optokinetic stimulation as squash, but who nevertheless have to achieve a high degree of physical skill. OKN, OKAN (frequency, slow phase velocity, and timeconstant), and latency to CV (Stage 2 and Stage 3) were measured using electro-oculographic recording inside an optokinetic drum. Contrary to predictions, there were no significant differences in OKN, OKAN, or latency to CV between the 2 groups. These results suggest that 1) the practice effects that alter the sensitivity to CV may decay relatively quickly, and 2) differences in recreational sporting activities between subjects may not be a significant confounding factor in visual-vestibular interaction experiments.
Asunto(s)
Postimagen/fisiología , Percepción de Movimiento/fisiología , Nistagmo Optoquinético/fisiología , Rotación , Adolescente , Adulto , Electrooculografía , Humanos , Masculino , Psicofísica , Deportes de Raqueta/fisiología , Sensación , Levantamiento de Peso/fisiologíaRESUMEN
The peripheral and central vestibular systems exhibit an age-related structural deterioration which may be responsible for vestibular reflex deficits and dizziness in the elderly. However, it seems likely that the central nervous system is capable of compensating for a certain degree of decline in function, since not all elderly people are impaired to the extent that the clinical signs of vestibular dysfunction are apparent. Dizziness and other vestibular disorders may develop only when the degree of deterioration of the vestibular system exceeds the ability of the nervous system to compensate. If dizziness does eventuate, it can have profound psychological consequences, particularly in terms of loss of confidence in independent activity, and may lead to the development of anxiety disorders. Vestibular rehabilitation programs may help to minimise the effects of age-related deterioration of the vestibular system and its psychological impact.
Asunto(s)
Envejecimiento/fisiología , Mareo/fisiopatología , Vestíbulo del Laberinto/fisiopatología , Anciano , Anciano de 80 o más Años , Circulación Cerebrovascular/fisiología , Trastornos Cerebrovasculares/fisiopatología , Mareo/etiología , Mareo/psicología , Oído Interno/fisiología , Oído Interno/fisiopatología , Células Ciliadas Vestibulares/fisiopatología , Humanos , Persona de Mediana Edad , Postura/fisiología , Reflejo Vestibuloocular/fisiología , Nervio Vestibular/fisiopatología , Núcleos Vestibulares/fisiopatología , Vestíbulo del Laberinto/anatomía & histología , Vestíbulo del Laberinto/fisiologíaRESUMEN
The aim of the present study was to investigate the effects of ageing on optokinetic function in labyrinthine-intact human subjects. Subjects aged 18-39 years, 40-59 years and > or = 60 years were tested for sensitivity to optokinetic stimulation using latency to the illusion of circularvection in an optokinetic drum. The latency to circularvection significantly increased with increasing age. These results suggest a decline in optokinetic sensitivity with increasing age, which may be related to age-related deterioration in the optokinetic visual pathways.